title: Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.
abstract: Assiduous surveillance for genetic aberrations is necessary in patients on cytotoxic therapies to detect therapy-related myeloid neoplasms (t-MN). Current modalities include metaphase cytogenetics and FISH. Since t-MN may develop abruptly in cytogenetically normal patients, a discussion exploring additional methods such as SNP-array and targeted-deep-sequencing to detect subchromosomal abnormalities is needed.
authors.affiliation: Department of Pathology, University of Arkansas for Medical Sciences 4301 W. Markham Street Slot 502, Little Rock, Arkansas, 72205.
authors.forename: Zeba N
authors.initials: ZN
authors.lastname: Singh
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.
authors.forename: Yogesh
authors.initials: Y
authors.lastname: Jethava
authors.affiliation: Department of Pathology, University of Arkansas for Medical Sciences 4301 W. Markham Street Slot 502, Little Rock, Arkansas, 72205.
authors.forename: Ginell R
authors.initials: GR
authors.lastname: Post
authors.affiliation: Department of Pathology, University of Arkansas for Medical Sciences 4301 W. Markham Street Slot 502, Little Rock, Arkansas, 72205.
authors.forename: Daisy
authors.initials: D
authors.lastname: Alapat
authors.affiliation: Department of Pathology, University of Arkansas for Medical Sciences 4301 W. Markham Street Slot 502, Little Rock, Arkansas, 72205.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Sawyer
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.
authors.forename: Sarah
authors.initials: S
authors.lastname: Waheed
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.
authors.forename: Bijay
authors.initials: B
authors.lastname: Nair
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.
authors.forename: Saad Z
authors.initials: SZ
authors.lastname: Usmani
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.
authors.forename: Clyde
authors.initials: C
authors.lastname: Bailey
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.
authors.forename: Nathan
authors.initials: N
authors.lastname: Petty
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.
authors.forename: Frits
authors.initials: F
authors.lastname: Van Rhee
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.
authors.forename: Bart
authors.initials: B
authors.lastname: Barlogie
keywords: Acute leukemia; cytogenetic abnormalities; myeloma; therapy-related myeloid neoplasm
references.citation: Semin Oncol. 1992 Feb;19(1):4-13
references.pmid: 1736369
references.citation: J Clin Oncol. 2011 Feb 10;29(5):504-15
references.pmid: 21220588
references.citation: Clin Transl Oncol. 2010 Jan;12(1):8-14
references.pmid: 20080465
references.citation: Blood. 2013 Jun 6;121(23):4753-7
references.pmid: 23603914
references.citation: N Engl J Med. 2011 Jun 30;364(26):2496-506
references.pmid: 21714648
references.citation: Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
references.pmid: 24030381
references.citation: Br J Pharmacol. 2011 Feb;162(4):792-805
references.pmid: 21039422
references.citation: Blood. 2008 Jan 1;111(1):94-100
references.pmid: 17895401
references.citation: Blood. 2010 May 27;115(21):4168-73
references.pmid: 20124509
references.citation: Leukemia. 2008 Feb;22(2):240-8
references.pmid: 18200041
references.citation: Blood. 2003 Feb 1;101(3):1128-40
references.pmid: 12393520
references.citation: Chem Biol Interact. 2010 Mar 19;184(1-2):39-45
references.pmid: 20026017
references.citation: Blood. 2006 Sep 15;108(6):2020-8
references.pmid: 16728703
references.citation: J Clin Oncol. 2012 Mar 10;30(8):820-9
references.pmid: 22331955
references.citation: Blood. 2011 Oct 13;118(15):4086-92
references.pmid: 21795746
references.citation: Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):110-4
references.pmid: 25107338
references.citation: Cancer Cell. 2011 Nov 15;20(5):591-605
references.pmid: 22094254
references.citation: Leukemia. 2014 Feb;28(2):241-7
references.pmid: 24220272
references.citation: Br J Haematol. 2007 Jul;138(2):176-85
references.pmid: 17593024
references.citation: Br J Haematol. 1996 Nov;95(2):349-53
references.pmid: 8904891
references.citation: Semin Oncol. 2008 Aug;35(4):418-29
references.pmid: 18692692
references.citation: Haematologica. 2009 Apr;94(4):454-9
references.pmid: 19336749
references.citation: Leukemia. 2008 Jul;22(7):1308-19
references.pmid: 18480833
references.citation: Leukemia. 2009 Jan;23(1):3-9
references.pmid: 18971951
references.citation: Carcinogenesis. 2004 May;25(5):749-55
references.pmid: 14688017
references.citation: Blood. 2012 Apr 12;119(15):3578-84
references.pmid: 22389253
references.citation: N Engl J Med. 2006 Mar 9;354(10):1021-30
references.pmid: 16525139